Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature

Neurology·MeSH: Myoclonus

Prevalence

700.0 / 100K

Incidence

48.0 / 100K/yr

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature?

There are 1 clinical trial targeting Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature tracked by BioSniper.

What is the prevalence of Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature?

The estimated prevalence of Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature is approximately 700.0 per 100,000 population.

Deep-dive into Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature — Drugs in Development & Clinical Trials | BioSniper